IGF-1R Inhibition for Proptosis Reduction in Thyroid Eye Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for moderate-to-severe thyroid eye disease (TED) are inadequate, with existing therapies like glucocorticoids and rituximab showing limited efficacy and safety concerns, and there is a need for alternative therapies that can effectively reduce symptoms such as proptosis and improve quality of life.
Innovation Solution
Administering an insulin-like growth factor-I receptor (IGF-1R) inhibitor, such as teprotumumab or other specified antibodies or small molecules, to target and inhibit IGF-1R signaling, thereby reducing proptosis, diplopia, and improving clinical activity scores and quality of life in TED patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids and rituximab are used to treat moderate-to-severe TED, then some symptom relief is achieved, but treatment efficacy is limited and safety concerns arise
Solution Approach 1:
The patent shifts the therapeutic approach by targeting a different molecular pathway (IGF-1R signaling) instead of using conventional immunosuppressants. This parameter change in the mechanism of action achieves superior efficacy in reducing proptosis and orbital tissue volume while maintaining a favorable safety profile, resolving the contradiction between effectiveness and safety
Solution Approach 2:
The invention extracts and targets the specific IGF-1R signaling pathway that drives orbital fibroblast activation and hyaluronic acid production, separating this pathogenic mechanism from the broader immune system. This selective targeting achieves effective symptom relief without the systemic side effects associated with conventional immunosuppressive therapies
2Ease of operation
If existing therapies are administered, then some clinical improvement occurs, but symptom reduction (particularly proptosis) is insufficient
Solution Approach 1:
The patent achieves precise symptom reduction by targeting IGF-1R signaling, which directly controls orbital tissue expansion through hyaluronic acid synthesis. This molecular-level parameter control enables significant proptosis reduction (mean decrease of 2.46 mm) and precise modulation of orbital tissue volume, overcoming the imprecision of conventional therapies
3Duration of action of moving object
If conventional treatments are used, then temporary symptom relief is achieved, but sustained benefits are not maintained after discontinuation
Solution Approach 1:
The patent implements preliminary action by administering IGF-1R inhibitors during the active phase of TED to prevent permanent structural changes in orbital tissues. By intervening early in the disease process and blocking the pathological signaling pathway before irreversible damage occurs, the treatment achieves sustained benefits that persist well beyond discontinuation, with patients maintaining improved symptoms long-term
Data Source
AI summary
Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.